The FDA is asking the healthcare industry how to regulate generative AI medical devices. We unpack their proposed competency-based approach, which evaluates AI less like software and more like a human medical resident.
Key points
Generative AI requires new regulatory frameworks because it produces variable outputs to similar inputs and can evolve after deployment.
The FDA proposes a two-axis framework to assess risk based on device activity (how independently it acts) and the consequences of an incorrect output.
A new competency-based premarket evaluation would mirror human clinician credentialing, using robust benchmarking and clinical confirmation.
Postmarket monitoring could involve periodic re-benchmarking and shared responsibility across the healthcare ecosystem to catch performance degradation.
The FDA suggests voluntary master files for foundation models, allowing developers to share underlying safety data without making it public.
This spot is available. Reach clinicians, health-system leaders and medtech and pharma teams following AI in medicine. Sponsor the show
This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.
Podden och tillhörande omslagsbild på den här sidan tillhör
Mike Rawson. Innehållet i podden är skapat av Mike Rawson och inte av,
eller tillsammans med, Poddtoppen.
